Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT05863845
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 40
- Registration Number
- NCT05864742
- Locations
- 🇦🇺
Flinders Medical Centre, Bedford Park, South Australia, Australia
🇦🇺Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT05861050
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 78
- Registration Number
- NCT05841771
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine Affilated Shanghai General Hospital, Shanghai, Shanghai, China
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05834244
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- PureTech
- Target Recruit Count
- 90
- Registration Number
- NCT05829226
- Locations
- 🇺🇸
Mass. General Hospital-Harvard, Boston, Massachusetts, United States
🇺🇸Virginia Commonwealth University Medical Center, Richmond, Virginia, United States
🇺🇸Baptist Health South Florida-Miami Cancer Institute, Miami, Florida, United States
Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Hematology department of the 920th hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05807347
- Locations
- 🇨🇳
Department of Hematology,920th Hospital of Joint Logistic Support Force of People's Liberation, Kunming, Yunnan, China
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 38
- Registration Number
- NCT05807932
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany
🇩🇪Universitätsklinikum Jena - Klinik für Innere Medizin II, Jena, Germany
🇩🇪Universitätsklinikum Aachen - Med. Klinik IV, Aachen, NRW, Germany
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
- Conditions
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Target Recruit Count
- 60
- Registration Number
- NCT05805098
- Locations
- 🇨🇳
Qiu Huiying, Suzhou, Jiangsu, China
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Sanjay Mohan
- Target Recruit Count
- 51
- Registration Number
- NCT05799079
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.